Baseline data from the ProtecT trial … with outcomes still to come

Many readers of this blog will be interested to look through the data on the preliminary study design and diagnostic and baseline results of the randomized, phase III ProtecT trial that have just been reported in The Lancet Oncology. … READ MORE …

New form of experimental immunotherapy for men with progressive mCRPC

A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination  with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

The “right” to investigational drug therapy “to save your life”

This November, voters in Arizona will get to determine whether, in their opinions, terminally ill patients should be entitled to have unfettered access to drugs that are in early-stage development but haven’t been approved by the U.S. Food and Drug Administration (FDA). … READ MORE …

Results of the RADAR trial at 7.4 years of follow-up

The RADAR trial (also known as TROG 03.04) was a randomized trial of 6 months of androgen deprivation therapy (ADT) + radiation therapy versus 18 months of ADT + radiotherapy, with or without additional zoledronic acid therapy, in men with intermediate- and high-risk, locally advanced prostate cancer. … READ MORE …

Short-term outcomes after prostate cancer diagnosis and treatment in France

An article available in full on the Medscape web site provides an overview of short-term outcomes of > 43,000 men diagnosed with prostate cancer in France in 2009 and followed for 2 years based on data in the French national health insurance information system (SNIIRAM). You do need to register with Medscape to be able to read the article (but registration is free). … READ MORE …

The value of metformin in management of prostate cancer: the debate continues

Available data offer both positive and negative evidence from observational studies regarding the value of metformin in the management of men newly diagnosed with prostate cancer. … READ MORE …

PSMs, risk, and recurrence after radical surgery for localized disease

A group of Brazilian researchers has clarified some issues related to risk associated with a positive surgical margin (PSM) after a radical prostatectomy. It is very clear that not all positive surgical margins come with the same level of risk. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,134 other followers